The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial
Open accessAbstract
Background Choroideremia is an X-linked recessive disease that leads to blindness due to mutations in the CHM gene, which encodes the Rab escort protein 1 (REP1). We assessed the effects of retinal gene therapy with an adeno-associated viral (AAV) vector encoding REP1 (AAV.REP1) in patients with this disease.Methods In a multicentre clinical trial, six male patients (aged 35-63 years) with choroideremia were administered AAV.REP1 (0·6-1·0×10(10) genome particles, subfoveal injection). Visual function tests included best corrected visual acuity, microperimetry, and retinal sensitivity tests for comparison of baseline values with 6 months after surgery. This study is registered with ClinicalTrials.gov, number NCT01461213.Findings Despite undergoing retinal detachment, which normally reduces vision, two patients with advanced choroideremia who had low baseline best corrected visual acuity gained 21 letters and 11 letters (more than two and four lines of vision). Four other patients with near normal best corrected visual acuity at baseline recovered to within one to three letters. Mean gain in visual acuity overall was 3·8 letters (SE 4·1). Maximal sensitivity measured with dark-adapted microperimetry increased in the treated eyes from 23·0 dB (SE 1·1) at baseline to 25·3 dB (1·3) after treatment (increase 2·3 dB [95% CI 0·8-3·8]). In all patients, over the 6 months, the increase in retinal sensitivity in the treated eyes (mean 1·7 [SE 1·0]) was correlated with the vector dose administered per mm(2) of surviving retina (r=0·82, p=0·04). By contrast, small non-significant reductions (p>0·05) were noted in the control eyes in both maximal sensitivity (-0·8 dB [1·5]) and mean sensitivity (-1·6 dB [0·9]). One patient in whom the vector was not administered to the fovea re-established variable eccentric fixation that included the ectopic island of surviving retinal pigment epithelium that had been exposed to vector.Interpretation The initial results of this retinal gene therapy trial are consistent with improved rod and cone function that overcome any negative effects of retinal detachment. These findings lend support to further assessment of gene therapy in the treatment of choroideremia and other diseases, such as age-related macular degeneration, for which intervention should ideally be applied before the onset of retinal thinning.Funding UK Department of Health and Wellcome Trust.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite a 28-day oral corticosteroid therapy started 2 days before the first IVT, a regimen similar to that provided in several other clinical studies using IVT or sub-retinal AAV-based gene therapies,41–45 70.7% of lenadogene nolparvovec-treated eyes developed some degree of intraocular inflammation versus 10.2% of placebo-treated eyes.”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As a consequence, wild-type AAV-based gene therapies for ophthalmologic indications generally require relatively high doses and/or administration via subretinal injection, an invasive surgical procedure that requires detachment of photoreceptors from the RPE and reportedly results in transduction of <5% of the retinal surface. 25 – 27”
From Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies (2024) · cites this paper as [26]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Although adeno-associated viral (AAV) vector-mediated retinal gene therapies have demonstrated efficacy”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, a recent phase I trial for choroideremia showed promising signs of efficacy.15”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“Adeno-associated virus has been successful in clinical gene therapy trials for Leber's congenital amaurosis, hemophilia, familial lipoprotein lipase deficiency, and choroideremia.8–15,26,27,60,61”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“A different approach to subretinal injection is a 'two-step ' injection with initiation of a small 'pre-bleb ' using balanced saline solution (BSS) followed by slow propagation of the bleb using the viral vector (MacLaren et al., 2014). A considerable advantage of two-step injection is that it allows bleb propagation at a lower injection pressure (Scruggs et al., 2022).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as MacLaren et al., 2014
In the citing paper
“Significant inflammation was also observed at 1 × 1011 vg in clinical trials for choroideremia.90,102”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [102]
In the citing paper
“Injection protocols dating to 2014 (30, 31) called for a 2-step procedure, which largely avoids causing a break in Bruch's membrane but does not completely eliminate the risk (20, 32).”
From Subretinal therapy: technological solutions to surgical and immunological challenges (2022) · cites this paper as [30]
In the citing paper
“while subretinal viral gene therapy has a favourable safety profile [300]”
From Bruch’s Membrane: A Key Consideration with Complement-Based Therapies for Age-Related Macular Degeneration (2023) · cites this paper as [300]
In the citing paper
“A phase I/II clinical trial of subretinal gene therapy using an AAV2 vector to deliver human REP1 to the outer retina has shown sustained preservation or improvement of visual acuity over 2 to 5 years in patients with advanced disease [MacLaren 2014, Xue 2018].”
From Correcting visual loss by genetics and prosthetics (2020) · cites this paper as MacLaren 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
LeWitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W., Eskandar, E. N., Kostyk, S. K., Thomas, K., Sarkar, A., Siddiqui, M. S., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70039-4 · Cited by 681
Self-citationJacobson, S. G. (2012) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.298 · Cited by 639
Sieving, P. A., Caruso, R. C., Tao, W., Coleman, H. R., Thompson, D. J. S., Fullmer, K. R., & Bush, R. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600236103 · Cited by 591
Cideciyan, A. V., Jacobson, S. G., Beltran, W. A., Sumaroka, A., Świder, M., Iwabe, S., Román, A. J., Olivares, M. B., Schwartz, S., Komáromy, A. M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218933110 · Cited by 441
AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness
Bennett, J., Ashtari, M., Wellman, J., Marshall, K. A., Cyckowski, L. L., Chung, D. C., McCague, S., Pierce, E. A., Chen, Y., Bennicelli, J. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002865 · Cited by 395
Retinal degeneration in choroideremia: deficiency of rab geranylgeranyl transferase
Seabra, M. C., Brown, M. S., & Goldstein, J. L. (1993) · Science · doi:10.1126/science.8380507 · Cited by 337
Self-citationCloning of a gene that is rearranged in patients with choroideraemia
Cremers, F. P. M., van de Pol, D. J. R., van Kerkhoff, L. P. M., Wieringa, B., & Ropers, H.-H. (1990) · Nature · doi:10.1038/347674a0 · Cited by 333
Self-citationLoeb, J. E., Cordier, W. S., Harris, M. E., Weitzman, M. D., & Hope, T. J. (1999) · Human Gene Therapy · doi:10.1089/10430349950016942 · Cited by 279
Cited by
Sorted by citations
Items 401–500 of 795
Dai, X., He, Y., Zhang, H., Zhang, Y., Liu, Y., Wang, M., Chen, H., & Pang, J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188032 · Cited by 20
Comparing Clinical Perimetry and Population Receptive Field Measures in Patients with Choroideremia
Silson, E. H., Alemán, T. S., Willett, A. E., Serrano, L. W., Pearson, D. J., Rauschecker, A. M., Maguire, A. M., Baker, C. I., Bennett, J., & Ashtari, M. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.18-23929 · Cited by 19
Hagag, A. M., Mitsios, A., Narayan, A. R., Abbouda, A., Webster, A. R., Dubis, A. M., & Moosajee, M. (2020) · Eye · doi:10.1038/s41433-020-0974-1 · Cited by 18
Self-citationVision research special issue: Sight restoration: Prosthetics, optogenetics and gene therapy
Fine, I., Cepko, C. L., & Landy, M. S. (2015) · Vision Research · doi:10.1016/j.visres.2015.04.012 · Cited by 24
Vision Impairment: Science, art and lived experience
Crossland, M. D. (2024) · UCL Press eBooks · doi:10.14324/111.9781800086227 · Cited by 18
Bildgebung und molekulargenetische Diagnostik zur Charakterisierung von Netzhautdystrophien
Birtel, J., Gliem, M., Holz, F. G., & Herrmann, P. (2018) · Der Ophthalmologe · doi:10.1007/s00347-018-0779-9 · Cited by 18
Viral Vectors in Gene Replacement Therapy
Minskaia, E., Galieva, A., Egorov, A. D., Ivanov, R. A., & Karabelsky, A. V. (2023) · Biochemistry (Moscow) · doi:10.1134/s0006297923120179 · Cited by 19
AAV Gene Augmentation Therapy for CRB1-Associated Retinitis Pigmentosa
Alves, C. H., & Wijnholds, J. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7522-8_10 · Cited by 18
Recent Advancements in Gene Therapy for Hereditary Retinal Dystrophies
Öner, A. (2017) · Turkish Journal of Ophthalmology · doi:10.4274/tjo.41017 · Cited by 19
Diagnóstico etiológico de la sordera infantil: recomendaciones de la CODEPEH
Núñez-Batalla, F., Jáudenes-Casaubón, C., Canet, J. M. S., Vivanco-Allende, A., Zubicaray-Ugarteche, J., & Farpón, R. C. (2016) · Acta Otorrinolaringológica Española · doi:10.1016/j.otorri.2016.05.002 · Cited by 18
Stevanovic, M., Cehajic‐Kapetanovic, J., Jolly, J. K., & MacLaren, R. E. (2019) · Acta Ophthalmologica · doi:10.1111/aos.14281 · Cited by 17
Self-citationLung gene therapy—How to capture illumination from the light already present in the tunnel
Xia, E., Munegowda, M. A., Cao, H., & Hu, J. (2014) · Genes & Diseases · doi:10.1016/j.gendis.2014.06.001 · Cited by 17
Chan, S., Bubela, T. M., Dimopoulos, I. S., Freund, P. R., Varkouhi, A. K., & MacDonald, I. M. (2016) · Ophthalmic Genetics · doi:10.3109/13816810.2015.1088958 · Cited by 17
Singh, M. S., Broadgate, S., Mathur, R., Holt, R., Halford, S., & MacLaren, R. E. (2016) · Scientific Reports · doi:10.1038/srep23674 · Cited by 17
Self-citationCHM/REP1 Transcript Expression and Loss of Visual Function in Patients Affected by Choroideremia
Iorio, V. D., Esposito, G., Falco, F. D., Boccia, R., Fioretti, T., Colucci, R., Rosa, G. D., Melillo, P., Salvatore, F., Simonelli, F., et al. (2019) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.18-25501 · Cited by 17
Content generation for patient-reported outcome measures for retinal degeneration therapeutic trials
Lacy, G. D., Abalem, M. F., Popova, L., Santos, E. P., Yu, G., Rakine, H. Y., Rosenthal, J. M., Ehrlich, J. R., Musch, D. C., & Jayasundera, T. (2020) · Ophthalmic Genetics · doi:10.1080/13816810.2020.1776337 · Cited by 17
Tan, T., Chan, H. W., Singh, M. S., Wong, T. Y., Pulido, J. S., Michaelides, M., Sohn, E. H., & Ting, D. S. W. (2021) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2021-319365 · Cited by 17
Aguilera, N., Liu, T., Bower, A. J., Li, J., Abouassali, S., Lu, R., Giannini, J., Pfau, M., Bender, C., Smelkinson, M. G., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03842-7 · Cited by 17
Ho, M. L., Judd, J., Kuypers, B. E., Yamagami, M., Wong, F. F., & Suh, J. (2014) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-014-0334-y · Cited by 17
Qizhao, W., Firrman, J., Wu, Z., Pokiniewski, K. A., Valencia, C. A., Wang, H., Wei, H., Zhuang, Z., Liu, L., Wunder, S. L., et al. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.055 · Cited by 17
Hughes, C., O’Flynn, N. M. J., Gatherer, M., McClements, M. E., Scott, J. A., MacLaren, R. E., Goverdhan, S. V., Glennie, M. J., & Lotery, A. J. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.11.005 · Cited by 17
Self-citationMannose-coupled AAV2: A second-generation AAV vector for increased retinal gene therapy efficiency
Mével, M., Pichard, V., Bouzelha, M., Álvarez‐Dorta, D., Lalys, P.-A., Provost, N., Allais, M., Mendes, A., Landagaray, E., Ducloyer, J., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101187 · Cited by 16
Multicenter Normative Data for Mesopic Microperimetry
Pfau, M., Jolly, J. K., Charng, J., von der Emde, L. A., Müller, P. L., Ansari, G., Pfau, K., Chen, F. K., & Wu, Z. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.12.27 · Cited by 16
Retinal gene therapy: current progress and future prospects
Ku, C. A., & Pennesi, M. E. (2015) · Expert Review of Ophthalmology · doi:10.1586/17469899.2015.1035711 · Cited by 16
Harrison, M. J., Birch, S., Eden, M., Ramsden, S., Farragher, T. M., Payne, K., Hall, G., & Black, G. C. M. (2015) · Journal of Community Genetics · doi:10.1007/s12687-014-0210-4 · Cited by 16
Self-citationMacular spatial distribution of preserved autofluorescence in patients with choroideremia
Hariri, A. H., Ip, M. S., Girach, A., Lam, B. L., Fischer, M. D., Sankila, E., Pennesi, M. E., Holz, F. G., MacLaren, R. E., Birch, D. G., et al. (2018) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2018-312620 · Cited by 16
Self-citationRamy, S., Ueda, Y., Nakajima, H., Hiroi, M., Hiroi, Y., Torisu, T., & Uchiyama, S. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.10.022 · Cited by 16
Advancing precision medicines for ocular disorders: Diagnostic genomics to tailored therapies
Panikker, P., Roy, S., Ghosh, A., Poornachandra, B., & Ghosh, A. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.906482 · Cited by 17
Jumelle, C., Mauclair, C., Houzet, J., Kress, B. C., Hé, Z., Forest, F., Perrache, C., Gain, P., & Thuret, G. (2016) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2015-307610 · Cited by 16
CRISPR GENOME SURGERY IN THE RETINA IN LIGHT OF OFF-TARGETING
Cho, G. Y., Schaefer, K. A., Bassuk, A. G., Tsang, S. H., & Mahajan, V. B. (2018) · Retina · doi:10.1097/iae.0000000000002197 · Cited by 15
Experimental gene therapies for the NCLs
Liu, W., Holthaus, S.-M. K., Herranz-Martín, S., Aristorena, M., Mole, S., Smith, A. J., Ali, R. R., & Rahim, A. A. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165772 · Cited by 18
MacLaren, R. E., Audo, I., Fischer, M. D., Huckfeldt, R. M., Lam, B. L., Pennesi, M. E., Sisk, R., Gow, J. A., Li, J., Zhu, K., et al. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.017 · Cited by 15
Self-citationExciting directions in glaucoma
Rasmussen, C. A., & Kaufman, P. L. (2014) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2014.08.007 · Cited by 15
The functional characteristics of optogenetic gene therapy for vision restoration
Lindner, M., Gilhooley, M. J., Peirson, S. N., Hughes, S., & Hankins, M. W. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03597-6 · Cited by 15
Desrosiers, M., & Dalkara, D. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7522-8_16 · Cited by 15
Identification and Analysis of Genes Associated with Inherited Retinal Diseases
Khan, M., Fadaie, Z., Cornelis, S. S., Cremers, F. P. M., & Roosing, S. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8669-9_1 · Cited by 14
Self-citationVSeq-Toolkit: Comprehensive Computational Analysis of Viral Vectors in Gene Therapy
Afzal, S., Fronza, R., & Schmidt, M. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.024 · Cited by 15
Clinical trials in retinal dystrophies
Eliott, D., Grob, S., Finn, A. P., & Papakostas, T. (2016) · Middle East African Journal of Ophthalmology · doi:10.4103/0974-9233.173135 · Cited by 19
Reid, C. A., Boye, S. L., Hauswirth, W. W., & Lipinski, D. M. (2017) · Gene Therapy · doi:10.1038/gt.2017.50 · Cited by 15
Genetics-based manipulation of adipose tissue sympathetic innervation
François, M., Qualls‐Creekmore, E., Berthoud, H., Münzberg, H., & Yu, S. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.08.024 · Cited by 14
Creating an Ocular Biofactory: Surgical Approaches in Gene Therapy for Acquired Retinal Diseases
Xu, D. N., Khan, M., & Ho, A. C. (2021) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000362 · Cited by 19
Optimized Subretinal Injection Technique for Gene Therapy Approaches
Mühlfriedel, R., Michalakis, S., Garrido, M. G., Sothilingam, V., Schön, C., Biel, M., & Seeliger, M. W. (2019) · Methods in Molecular Biology · doi:10.1007/978-1-4939-8669-9_26 · Cited by 14
van der Veen, I., Heredero Berzal, A., Koster, C., ten Asbroek, A. L. M. A., Bergen, A. A., & Boon, C. J. F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021267 · Cited by 14
van Schuppen, S. M., Talib, M., Bergen, A. A. B., ten Brink, J. B., Florijn, R. J., Boon, C. J. F., & van Schooneveld, M. J. (2017) · Retina · doi:10.1097/iae.0000000000001844 · Cited by 14
Choroideremia: The Endpoint Endgame
Elsayed, M. E. A. A., Taylor, L. J., Josan, A. S., Fischer, M. D., & MacLaren, R. E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814354 · Cited by 14
Self-citationSafety and Vision Outcomes Following Gene Therapy for Bietti Crystalline Dystrophy
Chen, X., Liu, X., Cui, S., Wang, G., Liu, Y., Qu, G., Jiang, L., Liu, Y., & Li, X. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.5619 · Cited by 14
Optical coherence tomography angiography and fundus autofluorescence in the eyes with choroideremia
Kato, M., Maruko, I., Koizumi, H., & Iida, T. (2017) · BMJ Case Reports · doi:10.1136/bcr-2016-217682 · Cited by 14
Xu, Y., Balasubramaniam, B., Copland, D. A., Liu, J., Armitage, M., & Dick, A. D. (2015) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-015-2961-y · Cited by 14
Therapeutic avenues for hereditary forms of retinal blindness
Kannabiran, C., & Mariappan, I. (2018) · Journal of Genetics · doi:10.1007/s12041-017-0880-x · Cited by 14
Insights on the intracellular trafficking of PDMAEMA gene therapy vectors
Bitoque, D. B., da Costa, A. M. R., & Silva, G. A. (2018) · Materials Science and Engineering C · doi:10.1016/j.msec.2018.07.071 · Cited by 14
Choroideremia: Update On Clinical Features And Emerging Treatments
Brambati, M., Borrelli, E., Sacconi, R., Bandello, F. M., & Querques, G. (2019) · Clinical ophthalmology · doi:10.2147/opth.s195564 · Cited by 14
Genome Surgery and Gene Therapy in Retinal Disorders.
Chan, L., Mahajan, V. B., & Tsang, S. H. (2017) · PubMed Central · Cited by 14
CHM mutation spectrum and disease: An update at the time of human therapeutic trials
Zeitz, C., Nassisi, M., Coriat, C., Andrieu, C., Boyard, F., Condroyer, C., Démontant, V., Antonio, A., Lancelot, M., Frederiksen, H. N., et al. (2021) · Human Mutation · doi:10.1002/humu.24174 · Cited by 14
Jia, R., Chen, S., Wang, L., Zhang, J., Qu, B., Qiao, J., Meng, X., Yu, S., Liu, X., Xu, B., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101377 · Cited by 15
Cruz-Pavlovich, F. J. S., Bolaños-Chang, A. J., Rio-Murillo, X. I. D., Aranda-Preciado, G. A., Razura-Ruiz, E. M., Santos, A., & Navarro‐Partida, J. (2024) · Cells · doi:10.3390/cells13020179 · Cited by 13
Genetic therapies and potential therapeutic applications of CRISPR activators in the eye
Ng, B., Kaukonen, M. K., McClements, M. E., Shamsnajafabadi, H., MacLaren, R. E., & Cehajic‐Kapetanovic, J. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101289 · Cited by 13
Self-citationWu, Z., McKendrick, A. M., Hadoux, X., Gaskin, J. C. F., Ang, G. S., Sarossy, M., & Crowston, J. G. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-19002 · Cited by 13
Gillespie, R. L., Lloyd, I. C., & Black, G. C. M. (2014) · Human Heredity · doi:10.1159/000362599 · Cited by 13
Self-citationDugel, P. U., Zimmer, C. N., & Shahidi, A. M. (2016) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2016.04.003 · Cited by 13
Measuring Central Retinal Sensitivity Using Microperimetry
Talib, M., Jolly, J. K., & Boon, C. J. F. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7522-8_25 · Cited by 13
Patrício, M. I., Barnard, A. R., Green, A. L., During, M. J., Sen, A., & MacLaren, R. E. (2017) · Seizure · doi:10.1016/j.seizure.2017.12.005 · Cited by 14
Self-citationWhat Is Next for Retinal Gene Therapy?Preprint
Vandenberghe, L. H. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017442 · Cited by 12
AAVrh-10 transduces outer retinal cells in rodents and rabbits following intravitreal administration
Zeng, Y., Qian, H., Wu, Z., Marangoni, D., Sieving, P. A., & Bush, R. A. (2019) · Gene Therapy · doi:10.1038/s41434-019-0094-3 · Cited by 12
Wu, F., He, W., Xiao, Y., Wu, Q., Zhang, Q., Zhang, T., Xu, L., & Pang, X. (2025) · Advanced Science · doi:10.1002/advs.202408397 · Cited by 12
Gene therapies for inherited retinal disorders
Farrar, G. J., Millington‐Ward, S., Chadderton, N., Mansergh, F. C., & Palfi, A. (2014) · Visual Neuroscience · doi:10.1017/s0952523814000133 · Cited by 12
Prins, D., Jansonius, N. M., & Cornelissen, F. W. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-20404 · Cited by 12
Role of Essential Metal Ions in AAV Vector-Mediated Transduction
Rambhai, H. K., Ashby, F. J., Qing, K., & Srivastava, A. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.019 · Cited by 11
Expression of Rab Prenylation Pathway Genes and Relation to Disease Progression in Choroideremia
Fry, L. E., Patrício, M. I., Jolly, J. K., Xue, K., & MacLaren, R. E. (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.8.12 · Cited by 12
Self-citationEssential cues of engineered polymeric materials regulating gene transfer pathways
Islam, M. A., Park, T., Firdous, J., Li, H.-S., Jiménez-Pérez, Z. E., Lim, M., Choi, J.-W., Yun, C., & Cho, C. (2022) · Progress in Materials Science · doi:10.1016/j.pmatsci.2022.100961 · Cited by 12
Gene therapy arrives at the macula
Scholl, H. P. N., & Sahel, J. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60033-7 · Cited by 12
Novel CHM mutations identified in Chinese families with Choroideremia
Cai, X., Huang, X., Tong, Y., Lu, Q., & Jin, Z. (2016) · Scientific Reports · doi:10.1038/srep35360 · Cited by 12
Deep Scleral Exposure: A Degenerative Outcome of End-Stage Stargardt Disease
Lee, W., Zernant, J., Nagasaki, T., Tsang, S. H., & Allikmets, R. L. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.07.018 · Cited by 12
Piperno, G. M., López‐Requena, A., Predonzani, A., Dorvignit, D., Labrada, M., Zentilin, L., Burrone, Ó. R., & Cesco-Gaspere, M. (2015) · Gene Therapy · doi:10.1038/gt.2015.71 · Cited by 12
Yang, L., Ijaz, I., Cheng, J., Wei, C., Tan, X., Khan, M. A., Fu, X., & Fu, J. (2017) · The Application of Clinical Genetics · doi:10.2147/tacg.s144383 · Cited by 12
Bellingrath, J.-S., Li, K. V., Aziz, K., Izzi, J. M., Liu, Y., & Singh, M. S. (2024) · Frontiers in Ophthalmology · doi:10.3389/fopht.2024.1377098 · Cited by 11
Clinical applications of retinal gene therapies
Fu, X., Huu, V. A. N., Duan, Y., Kermany, D., Valentim, C. C. S., Zhang, R., Zhu, J., Zhang, C. L., Sun, X., & Zhang, K. (2018) · Precision Clinical Medicine · doi:10.1093/pcmedi/pby004 · Cited by 12
The Role of Rab GTPases in the development of genetic and malignant diseases
Erol, Ö. D., Şenocak, Ş., & Aerts‐Kaya, F. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04727-x · Cited by 11
CRISPRi-Mediated Treatment of Dominant Rhodopsin-Associated Retinitis Pigmentosa
Burnight, E. R., Wiley, L. A., Mullin, N. K., Adur, M. K., Lang, M. J., Cranston, C. M., Jiao, C., Russell, S. R., Sohn, E. H., Han, I. C., et al. (2023) · The CRISPR Journal · doi:10.1089/crispr.2023.0039 · Cited by 11
Shamsnajafabadi, H., Kaukonen, M. K., Bellingrath, J.-S., MacLaren, R. E., & Cehajic‐Kapetanovic, J. (2024) · Genes · doi:10.3390/genes15050625 · Cited by 11
Self-citationGene therapies in clinical trials
Papadopoulos, K. I., Wattanaarsakit, P., Prasongchean, W., & Narain, R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-08-100520-0.00010-2 · Cited by 11
Gene therapy approaches for the treatment of retinal disorders.
Petit, L., & Punzo, C. (2016) · PubMed · Cited by 11
Outcome of Full-Thickness Macular Hole Surgery in Choroideremia
Talib, M., Koetsier, L., MacLaren, R. E., & Boon, C. J. F. (2017) · Genes · doi:10.3390/genes8070187 · Cited by 11
Self-citationLenassi, E., de Carvalho, A. C., Thormann, A., Abrahams, L., Arno, G., Fletcher, T. A., Hardcastle, C. L., Lopez, J., Hunt, S. E., Short, P., et al. (2023) · Journal of Medical Genetics · doi:10.1136/jmg-2022-108618 · Cited by 11
Self-citationColour discrimination ellipses in choroideremia
Seitz, I. P., Jolly, J. K., Fischer, M. D., & Simunovic, M. P. (2018) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-018-3921-0 · Cited by 11
Poli, F. E., Yusuf, I. H., Jolly, J. K., Taylor, L. J., Adeyoju, D., Josan, A. S., Birtel, J., Issa, P. C., Cehajic‐Kapetanovic, J., da Cruz, L., et al. (2023) · Translational Vision Science & Technology · doi:10.1167/tvst.12.9.24 · Cited by 10
Self-citationMacLaren, R. E., Lam, B. L., Fischer, M. D., Holz, F. G., Pennesi, M. E., Birch, D. G., Sankila, E., Meunier, I., Stepien, K. E., Sallum, J. M. F., et al. (2024) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2024.01.022 · Cited by 10
Self-citationCehajic‐Kapetanovic, J., Bellini, M. P., Taylor, L. J., Yusuf, I. H., Soomro, T., da Cruz, L., & MacLaren, R. E. (2024) · Efficacy and Mechanism Evaluation · doi:10.3310/wara5730 · Cited by 11
Self-citationGene expression changes during retinal development and rod specification.
Mansergh, F. C., Carrigan, M., Hokamp, K., & Farrar, G. J. (2015) · Europe PMC (PubMed Central) · Cited by 10
Co-transduction of dual-adeno-associated virus vectors in the neonatal and adult mouse utricles
Chen, Z.-R., Guo, J., He, L., Liu, S., Xu, J.-Y., Yang, Z.-J., Su, W., Liu, K., Gong, S., & Wang, G. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1020803 · Cited by 10
Adeno-Associated Viral Gene Therapy for Retinal Disorders
Silva, S. R. D., McClements, M. E., Hankins, M. W., & MacLaren, R. E. (2015) · Neuromethods · doi:10.1007/978-1-4939-2306-9_9 · Cited by 10
Self-citationGalli, A., Latta, V. D., Bologna, C., Pucciarelli, D., Cipriani, F., Backovic, A., & Cervelli, T. (2017) · Journal of Applied Microbiology · doi:10.1111/jam.13511 · Cited by 10
Recording and Analysis of Goldmann Kinetic Visual Fields
Talib, M., Dagnelie, G., & Boon, C. J. F. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7522-8_24 · Cited by 10
Tsang, S. H., & Sharma, T. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-95046-4_9 · Cited by 10
Peripapillary Intravitreal Injection Improves AAV-Mediated Retinal Transduction
Madrakhimov, S. B., Yang, J. Y., Ahn, D. H., Han, J. W., Ha, T. H., & Park, T. K. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.018 · Cited by 10
La conception de vecteurs adaptés à la thérapie génique oculaire
Khabou, H., & Dalkara, D. (2015) · médecine/sciences · doi:10.1051/medsci/20153105015 · Cited by 11
Paradigm Shifts in Ophthalmic Diagnostics.
Sebag, J., Sadun, A. A., & Pierce, E. A. (2016) · Europe PMC (PubMed Central) · Cited by 10
Participant perspectives on a phase I/II ocular gene therapy trial (NCT02077361)
Brooks, S. P., Benjaminy, S., & Bubela, T. M. (2019) · Ophthalmic Genetics · doi:10.1080/13816810.2019.1630843 · Cited by 10
COG5 variants lead to complex early onset retinal degeneration, upregulation of PERK and DNA damage
Tabbarah, S., Tavares, E. S., Charish, J., Vincent, A., Paterson, A. D., Scipio, M. D., Yin, Y., Mendoza‐Londono, R., Maynes, J. T., Héon, E., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-77394-3 · Cited by 9
Fischer, M. D. (2016) · Ophthalmologica · doi:10.1159/000445782 · Cited by 9
Salvetti, A. P., Patrício, M. I., Barnard, A. R., Orlans, H. O., Hickey, D. G., & MacLaren, R. E. (2017) · Translational Vision Science & Technology · doi:10.1167/tvst.6.4.4 · Cited by 9
Self-citation
Metadata
- Authors
- MacLaren, R. E., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Seymour, L., Clark, K. R., During, M. J., Cremers, F. P. M., Black, G. C. M., Lotery, A. J., Downes, S. M., Webster, A. R., & Seabra, M. C.
- Affiliations
- Moorfields Eye Hospital NHS Foundation Trust (GB)
- University of Oxford (GB)
- NIHR Oxford Biomedical Research Centre (GB)
- Imperial College London (GB)
- Nationwide Children's Hospital (US)
- The Ohio State University Wexner Medical Center (US)
- Radboud University Nijmegen (NL)
- Manchester Academic Health Science Centre (GB)
- University of Southampton (GB)
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2014-03
- Volume
- 383
- Issue
- 9923
- Pages
- 1129-1137
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC4171740
- OpenAlex
- W2126115955
- Cited by
- 796
- References
- 28
- Citations by year
- 2026: 24 · 2025: 29 · 2024: 46 · 2023: 42 · 2022: 37 · 2021: 62 · 2020: 68 · 2019: 78 · 2018: 85 · 2017: 109 · 2016: 80 · 2015: 83 · 2014: 51
- FWCI
- 44.12
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Lancet (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- Wellcome Trust (091984)
- Cancer Research UK (11339)
- National Institute for Health and Care Research (NF-SI-0509-10185)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- choroideremia, retinal gene therapy, adeno-associated virus vectors, Rab escort protein 1, CHM gene, X-linked retinal degeneration, visual acuity improvement, retinal sensitivity, microperimetry, retinal detachment, vector dose, rod and cone function, retinal pigment epithelium, eccentric fixation, blindness treatment
- MeSH terms
- Adenoviridae, Adult, Aged, Fluorescence, Genetic Vectors, Humans, Male, Middle Aged, Retinal Detachment, Visual Acuity, Genetic Therapy, Choroideremia, Gene Transfer Techniques, Transgenes, Adaptor Proteins, Signal Transducing, Injections, Intraocular
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
